Alliance Pharma buys rights to Novartis' obstetric drug Syntometrine
June 6 (Reuters) - Specialty pharmaceutical company Alliance Pharma Plc said it bought all existing rights to obstetric drug Syntometrine from Novartis AG for $11.5 million.
Alliance Pharma, which acquires, markets and distributes pharmaceutical products, already owns the UK rights to Syntometrine, a drug used in the final stage of labour.
Sales of Syntometrine by Novartis were $3.2 million and gross margin was $2.8 million in the 12 months to March 2013, the company said in a statement.
Alliance Pharma, which generated 44.9 million pounds in revenue last year, said it would fund the acquisition from cash on hand and bank facilities, including a 3.5 million pound ($5.39 million) drawdown from its 30 million pounds acquisition facilities.
- Malaysian PM says lost airliner was diverted deliberately |
- Malaysia PM says lost plane's movements indicate a deliberate act
- Exclusive: Radar data suggests missing Malaysia plane deliberately flown way off course - sources
- UPDATE 2-Satellite data shows missing Malaysia plane may have flown thousands of miles-source
- UPDATE 1-Rolls-Royce concurs with Malaysia on missing jet's engine data